Carol J. Thiele, Ph.D.

Carol J. Thiele, Ph.D.

  • Center for Cancer Research
  • National Cancer Institute
  • Building 10 - Hatfield CRC, Room 1W- 3940 (office)
  • Bethesda, MD 20892-1928
  • 240-858-3849


Dr. Thiele leads a research program which develops novel therapies for children with solid tumors using state-of-the-art biologic and genomic analyses of tumors and normal counterparts. She pioneered studies using retinoids to “target” the MYCN oncogene and control tumor growth. These led to clinical studies which showed that retinoids improved outcomes for children with high-risk neuroblastoma.

Her section has developed pre-clinical models and genetically engineered mice (GEMs) to study mechanisms of neuroblastoma tumorigenesis and assess novel therapeutic interventions. Ongoing studies are aimed at understanding epigenetic/chromatin based mechansims to re-program and differentiate neuroblastoma tumor cells.

Areas of Expertise


Selected Key Publications

CASZ1 induces skeletal muscle and rhabdomyosarcoma differentiation through a feed-forward loop with MYOD and MYOG

Liu Z, Zhang X, Lei H, Lam N, Carter S, Yockey O, Xu M, Mendoza A, Hernandez ER, Wei JS, Khan J, Yohe ME, Shern JF, Thiele CJ.
Nat Commun. 11(1): 911, 2020. [ Journal Article ]

Targeting the Chromosomal Passenger Complex Subunit INCENP Induces Polyploidization, Apoptosis, and Senescence in Neuroblastoma

Sun M, Veschi V, Bagchi S, Xu M, Mendoza A, Liu Z, Thiele CJ.
Cancer Res. 79(19): 4937-50, 2019. [ Journal Article ]

CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2

Chen L, Alexe G, Dharia NV, Ross L, Iniguez AB, Conway AS, Wang EJ, Veschi V, Lam N, Qi J, Gustafson WC, Nasholm N, Vazquez F, Weir BA, Cowley GS, Ali LD, Pantel S, Jiang G, Harrington WF, Lee Y, Goodale A, Lubonja R, Krill-Burger JM, Meyers RM, Tsherniak A, Root DE, Bradner JE, Golub TR, Roberts CW, Hahn WC, Weiss WA, Thiele CJ, Stegmaier K.
J Clin Invest. 128(1): 446-62, 2018. [ Journal Article ]

When LMO1 Meets MYCN, Neuroblastoma Is Metastatic

Liu Z, Thiele CJ.
Cancer Cell. 32(3): 273-5, 2017. [ Journal Article ]

Epigenetic siRNA and Chemical Screens Identify SETD8 Inhibition as a Therapeutic Strategy for p53 Activation in High-Risk Neuroblastoma

Veschi V, Liu Z, Voss TC, Ozbun L, Gryder B, Yan C, Hu Y, Ma A, Jin J, Mazur SJ, Lam N, Souza BK, Giannini G, Hager GL, Arrowsmith CH, Khan J, Appella E, Thiele CJ.
Cancer Cell. 31(1): 50-63, 2017. [ Journal Article ]

Job Vacancies

We have no open positions in our group at this time, please check back later.

To see all available positions at CCR, take a look at our Careers page. You can also subscribe to receive CCR's latest job and training opportunities in your inbox.


News from Our Lab


2017 AACR Aflac Scholar-in-Training Award

  • Veronica Veschi, M.D., Ph.D. 

2017 17th CCR-FYI Colloquium - Outstanding Oral Presentation

  • Veronica Veschi, M.D., Ph.D.             
Veronica Veschi
Veronica Veschi


Advances In Neuroblastoma Research 2016 – Best Abstracts​

  • Deblina Banerjee - Reactivation of cAMP PKA pathway is an early even that relieves EZH2-mediated epigenetic suppression in High-Risk Neuroblastoma (HR-NB)


Advances In Neuroblastoma Research 2014 – Best Abstracts

  • ​Carol Thiele, Zhihui Liu - Whole Genome Screen to identify genes targeting MYCN driven embryonic tumors - Neuroblastoma model